SD4 Stock Chart & Stats
€0.80
€0.01(1.19%)
At close: 4:00 PM EDT
€0.80
€0.01(1.19%)
Day’s Range― - ―
52-Week Range€0.66 - €0.96
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€198.17M
Enterprise Value€411.25M
Total Cash (Recent Filing)€803.00K
Total Debt (Recent Filing)€25.68M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Nov 06, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding294,640,630
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-5.93
Price to Sales (P/S)169.36
P/FCF Ratio-42.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€1.76M
Bulls Say, Bears Say
Bulls Say
Specialized Critical-care PlatformA focused platform spanning both a targeted therapy and a companion diagnostic gives Spectral a coherent clinical strategy in septic shock. If validation and adoption progress, the linked products could support differentiated treatment selection and a broader commercial opportunity.
Recent Loss ReductionA narrower net loss indicates some improvement in reported operating performance compared with the prior year, even though profitability remains deeply negative. Sustaining this direction could gradually reduce the scale of funding required as the company advances its clinical-stage programs.
Cash Losses Track Accounting LossesCash consumption broadly matching reported losses suggests the company is not currently experiencing a materially worse cash-conversion profile than its income statement implies. This provides some clarity on funding needs, although the absolute burn remains substantial and requires improvement.
Bears Say
Small And Declining Revenue BaseVery limited revenue scale and a recent decline constrain the company’s ability to fund development internally or absorb fixed operating costs. The inconsistent top-line history also makes it difficult to establish durable commercial momentum over the next several quarters.
Severely Negative ProfitabilityGross losses and an extremely negative net margin show that current operations are far from an economically sustainable model. Without substantial improvement in commercialization, pricing, or costs, ongoing losses can continue consuming capital and weaken the company’s strategic flexibility.
Stressed Balance Sheet And Financing RiskNegative equity, sharply higher debt, and a very thin asset base leave little balance-sheet cushion against continued operating losses. This weak financial position increases dependence on external financing and may constrain investment capacity or create dilution and solvency pressure.
Spectral Medical News
SD4 FAQ
What was Spectral Medical’s price range in the past 12 months?
Spectral Medical lowest stock price was €0.66 and its highest was €0.95 in the past 12 months.
What is Spectral Medical’s market cap?
Spectral Medical’s market cap is €198.17M.
When is Spectral Medical’s upcoming earnings report date?
Spectral Medical’s upcoming earnings report date is Nov 06, 2026 which is in 18 days.
How were Spectral Medical’s earnings last quarter?
Spectral Medical released its earnings results on Aug 07, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.006 by €0.006.
Is Spectral Medical overvalued?
According to Wall Street analysts Spectral Medical’s price is currently Overvalued.
Does Spectral Medical pay dividends?
Spectral Medical does not currently pay dividends.
What is Spectral Medical’s EPS estimate?
Spectral Medical’s EPS estimate is >-0.01.
How many shares outstanding does Spectral Medical have?
Spectral Medical has 294,640,630 shares outstanding.
What happened to Spectral Medical’s price movement after its last earnings report?
Spectral Medical reported an EPS of €0 in its last earnings report, beating expectations of -€0.006. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Spectral Medical?
Currently, no hedge funds are holding shares in DE:SD4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spectral Medical
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Technical Analysis
Cipher Pharmaceuticals
―
BioMark Diagnostics
―
―
Profound Medical
―
Sona Nanotech Inc
―